Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiObex initiates trial of diabetes drug
There are convincing data supporting the concept that abnormalities in cortisol activity are an important cause of insulin resistance, visceral fat deposition, elevated cholesterol and blood pressure. These
There are convincing data supporting the concept that abnormalities in cortisol activity are an important cause of insulin resistance, visceral fat deposition, elevated cholesterol and blood pressure. These
The trial, which enrolled 103 patients in the US and Canada, studied the effect of a 12 week treatment of CRx-140 compared to low-dose cyclosporine. However, the drug
This study will evaluate the tolerability, safety, and pharmacokinetics of IMS in normal human volunteers. IMS represents Inotek’s the second compound to have entered clinical trials The company
A six-month priority review is a significant acceleration of the standard review process for new drugs which takes ten months. Priority review is granted to drugs that, if
Although no intravenous formulation has ever been available in the US, other formulations of acetaminophen have been available for over 50 years. IV APAP has, however, been marketed
The companies now plan to progress the development of the compounds into the next phase, focused on compound optimization and advancement of the program towards development. Under the
Anturol, which utilizes Antares’ proprietary advanced transdermal delivery (ATD) gel platform, is expected to begin pivotal phase III clinical trials during the second half of 2006. Oxybutynin, the
Axcan said that it will decide on whether or not to continue developing the drug in its functional dyspepsia indication after it has further evaluated data from the
This designation will provide a 10-year period of market exclusivity if AS1411 is approved as a treatment for either disease. The drug already has US orphan drug status
The fast track development program facilitates development and expedites regulatory review of drugs intended to address an unmet medical need for serious or life-threatening conditions. PRO 140 belongs